Senseonics and Beta Bionics Partner on Development of the Bionic Pancreas System
June 07 2018 - 7:44AM
Business Wire
Long-term, implantable continuous glucose sensor to be
integrated with bionic pancreas system
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical
technology company focused on the development and commercialization
of transformative glucose monitoring products, and Beta Bionics, a
medical technology company leveraging machine learning artificial
intelligence to develop and commercialize the world’s first
autonomous bionic pancreas, today announced that they have entered
into a development agreement to integrate glucose data from the
Eversense® Continuous Glucose Monitoring (CGM) system into the iLet
Bionic Pancreas system.
The Eversense CGM system is a long-term, implantable continuous
glucose monitoring system that continually measures interstitial
fluid glucose levels and wirelessly sends the readings to a
smartphone application. The iLet Bionic Pancreas system is a
dual-chamber, autonomous, infusion pump that mimics a biological
pancreas by automatically and autonomously adapting insulin and
glucagon dosing to meet the individual needs of a person with
diabetes.
“We are very excited to partner with Beta Bionics to integrate
our long-term glucose sensor with the bionic pancreas system,” said
Tim Goodnow, President and CEO of Senseonics. “The combination of
these two technologies could create a unique option for increased
simplicity, convenience and confidence in diabetes management. We
are pleased to be working with the Beta Bionics team as they
advance a real breakthrough for people with diabetes.”
“Senseonics has generated impressive clinical data demonstrating
the remarkable accuracy of their Eversense CGM system and providing
a categorically different CGM alternative for people with
diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We
believe that only highly accurate, reliable and safe sensors are
suitable for driving automated insulin delivery systems. Based on
clinical data from multiple clinical studies, the Eversense CGM
system appears to meet these high standards. We are excited to
partner with Senseonics to help make the iLet Bionic Pancreas
system a platform of choice for people with diabetes – one that
will ultimately allow people to choose between multiple CGMs, to
choose between multiple insulin types, and to choose glucagon.”
Under this development agreement, Beta Bionics will work with
Senseonics to integrate the Eversense CGM system with the iLet, so
that real-time Eversense data may serve as one CGM option to drive
the fully autonomous iLet Bionic Pancreas system.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of glucose
monitoring products designed to help people with diabetes
confidently live their lives with ease. Senseonics’ first
generation continuous glucose monitoring (CGM) system, Eversense®,
includes a small sensor, smart transmitter and mobile application.
Based on fluorescence sensing technology, the sensor is designed to
be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile
device. After insertion, the sensor is designed to continually and
accurately measure glucose levels. For more information on
Senseonics, please visit www.senseonics.com.
About Beta Bionics
Beta Bionics is a for-profit Massachusetts public benefit
corporation founded in 2015 to commercialize the iLet, a
revolutionary bionic pancreas that is driven by machine-learning
mathematical dosing algorithms, which incorporate artificial
intelligence to autonomously control glycemia. These dosing
algorithms were developed in the Damiano Lab at Boston University
and refined based on results from home-use clinical trials in
adults and children with T1D. Beta Bionics is a Certified B
Corporation™ whose founders—in addition to Ed Damiano—include other
parents of children with type 1 diabetes. Beta Bionics is committed
to acting in the best interests of the diabetes community and to
profoundly disrupting the diabetes medical device industry by
bringing the iLet to market as expeditiously and responsibly as
possible. Beta Bionics is pursuing regulatory approval of its
insulin-only bionic pancreas, which will be followed by its
dual-hormone system that will also administer a glucagon analog in
order to raise blood-sugar levels without the need to consume
carbohydrates.
Beta Bionics is headquartered in Boston, Massachusetts with
certain operations in Irvine, California. For further information,
please visit www.betabionics.com or follow Beta Bionics Facebook,
YouTube, Instagram, LinkedIn and Twitter @BetaBionics.
Forward Looking Statements
Certain statements contained in this press release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute “forward-looking statements.” These
forward-looking statements reflect Senseonics’ current views about
its plans, intentions, expectations, strategies and prospects,
including statements concerning the potential integration of the
Eversense CGM system with Beta Bionics’ Bionic Pancreas and the
potential benefits to patients of the combination of these
technologies. Although Senseonics believes that its plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable,
Senseonics can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond Senseonics’ control.
Other risks and uncertainties are more fully described in the
section entitled “Risk Factors” in Senseonics’ Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 13, 2018, its Quarterly Report on Form 10-Q filed with the
SEC on May 10, 2018 and its other SEC filings. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. The statements made in this press release speak only as of
the date stated herein, and subsequent events and developments may
cause Senseonics’ expectations and beliefs to change. While
Senseonics may elect to update these forward-looking statements
publicly at some point in the future, Senseonics specifically
disclaims any obligation to do so, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180607005609/en/
Senseonics Holdings, Inc.INVESTOR CONTACTR. Don
ElseyChief Financial
Officer301-556-1602don.elsey@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From May 2023 to May 2024